A new technique for reducing the burden of ovarian tumors in mice might be available for testing in humans within 18 to 24 months.

Although early-stage ovarian cancer sometimes responds to surgery followed by chemotherapy, there are no effective treatments for advanced ovarian cancer that has recurred after surgery and primary chemotherapy. Therefore, most treated early-stage cancers recur.

Read the rest of this entry »

A new test, called OVA1 (Vermillion, Inc.), can help detect ovarian cancer in a pelvic mass. OVA1 drug identifies some women who will benefit from referral to a gynecological oncologist for surgery despite negative results from other tests for ovarian cancer. If other test results suggest cancer, referral to an oncologist is appropriate even with a negative OVA1 result.

Read the rest of this entry »